Not only that, but corneal scarring is an unmet medical need. Right now doctors can either prescribe steroid injections, or have to perform surgery. With topical eye drops it would make quality of life easier.
That's my biggest consideration for investing in RXII. They are in markets that have a huge unmet medical need.
1.) there is no drug for corneal scarring 2.) there is no drug for retinal scarring in Wet AMD patients
This company will be successful it may take some time but it will be worth it.